<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36825522</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-8405</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>AIDS research and human retroviruses</Title><ISOAbbreviation>AIDS Res Hum Retroviruses</ISOAbbreviation></Journal><ArticleTitle>Immune Cell Cross Talk in the Establishment of Human Immunodeficiency Virus-1 Latency.</ArticleTitle><Pagination><StartPage>318</StartPage><EndPage>331</EndPage><MedlinePgn>318-331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/AID.2022.0062</ELocationID><Abstract><AbstractText>Revolutionary progress in combinational antiretroviral therapy has transformed human immunodeficiency virus (HIV) infection into a chronic manageable disease; yet, there exists an uneasy truce between the virus and the immune cells, where inflammation is limited but infection continues to fester from latent reservoirs of the virus. Clinical studies have identified the major immune cell types that constitute the latent HIV-1 reservoirs as monocytes/macrophages and CD4+ T cells. Latency probing approaches have thrown some light on the interaction between the virus and the reservoir cells from the time of onset of infection. However, research combining latency reversal strategies and immunotherapies face daunting obstacles in clinical trials because of the lack of in-depth knowledge on viral pathogenesis and mechanisms of viral evasion, leaving us behind in the battle for HIV cure. This article reviews existing knowledge on the cells and mechanisms that contribute to the establishment and survival of HIV reservoirs in infected individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rachel</LastName><ForeName>Gladys</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4891-0391</Identifier><AffiliationInfo><Affiliation>Laboratory Division, ICMR-National Institute of Epidemiology, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vembuli</LastName><ForeName>Hemanathan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology &amp; Biotechnology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar Chethrapilly Purushothaman</LastName><ForeName>Girish</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory Division, ICMR-National Institute of Epidemiology, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Luke Elizabeth</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Virology &amp; Biotechnology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIDS Res Hum Retroviruses</MedlineTA><NlmUniqueID>8709376</NlmUniqueID><ISSNLinking>0889-2229</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017735" MajorTopicYN="N">Virus Latency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD4 + T lymphocytes</Keyword><Keyword MajorTopicYN="N">HIV-1 latency</Keyword><Keyword MajorTopicYN="N">cross talk</Keyword><Keyword MajorTopicYN="N">macrophages</Keyword><Keyword MajorTopicYN="N">reservoirs</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36825522</ArticleId><ArticleId IdType="doi">10.1089/AID.2022.0062</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>